Approach

Strategy with the
discretion of a private firm.

Methodology

How we work.

01

Diagnose with rigor.

We begin with the unsentimental view: what frontier AI can credibly deliver inside your regulatory and clinical environment — and what it cannot. Diligence draws on direct experience across R&D, regulatory, and commercial functions.

02

Architect for permanence.

We design strategy and governance that outlast leadership cycles. Frameworks are auditable, defensible, and operationally light — built so institutional adoption is possible, not just announceable.

03

Deliver across stakeholders.

From C-suite and Board, through clinical and regulatory teams, to ministerial and multilateral counterparts, we translate technical detail into precise decisions for each audience.

Industries

Whom we serve.

  • PharmaGlobal pharmaceutical companies navigating frontier AI across discovery, development, and commercialization.
  • BiotechEmerging biotechs structuring AI-native platforms, alliances, and capital strategy.
  • Global HealthMultilateral institutions, ministries, and access organizations working at the intersection of AI and equity.
  • InvestorsStrategic and financial investors evaluating AI assets and platforms in life sciences.

Engagement Models

Ways to work together.

Advisory Retainer

Ongoing senior counsel for executive teams making frontier-AI portfolio, governance, and partnership decisions.

Defined Engagement

Time-boxed projects: portfolio prioritization, governance framework design, partnership structuring, or access strategy.

Board & Diligence

Discrete board, audit-committee, and investor diligence work on AI strategy, AI assets, and platform partnerships.